Comparative Pharmacology
Head-to-head clinical analysis: BETAXON versus CARTEOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXON versus CARTEOLOL HYDROCHLORIDE.
BETAXON vs CARTEOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
Non-selective beta-adrenergic receptor antagonist (beta-blocker) with intrinsic sympathomimetic activity (ISA) and weak local anesthetic (membrane-stabilizing) activity. Reduces intraocular pressure by decreasing aqueous humor production.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
Ophthalmic: Instill 1 drop of 1% or 2% solution into affected eye(s) twice daily. Oral: 2.5 mg to 5 mg once daily; may increase to 10 mg once daily if needed. Maximum dose 10 mg daily.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Terminal elimination half-life is 5-6 hours in patients with normal renal function; may extend to 24-36 hours in severe renal impairment.
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Renal excretion of unchanged drug and active metabolite (8-hydroxycarteolol) accounts for 50-70% of elimination. Biliary/fecal excretion is minimal (<10%).
Category C
Category C
Beta-Blocker
Beta-Blocker